BLA 021149 · Emd Serono
Ovidrel
Choriogonadotropin Alfa · Injection, Subcutaneous · Gonadotropin
Last checked: Nov 20, 2026Latest source record: Sep 30, 2015 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2000
Sep 20, 2000
Approved uses
1
Original approval plus efficacy supplements
Registered trials
75
17 Phase 3, 5 recruiting
FAERS reports
1,163
924 serious, 25 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Dec 26, 2023.
INDICATIONS AND USAGE Ovidrel ® PreFilled Syringe (choriogonadotropin alfa injection) is indicated for the induction of final follicular maturation and early luteinization in infertile women who have undergone pituitary desensitization and who have been appropriately pretreated with follicle stimulating hormones as part of an Assisted Reproductive Technology (ART) program such as in vitro fertilization and embryo transfer. Ovidrel ® PreFilled Syringe is also indicated for the induction of ovulation (OI) and pregnancy in anovulatory infertile patients in whom the cause of infertility is functional and not due to primary ovarian failure. Selection of Patients Before treatment with gonadotropins is instituted, a thorough gynecologic and endocrinologic evaluation must be performed. This should include an assessment of pelvic anatomy. Patients with tubal obstruction should receive Ovidrel ® PreFilled Syringe only if enrolled in an in vitro fertilization program. Primary ovarian failure should be excluded by the determination of gonadotropin levels. Appropriate evaluation should be performed to exclude pregnancy. Patients in later reproductive life have a greater predisposition to endometrial carcinoma as well as a higher incidence of anovulatory disorders. A thorough diagnostic evaluation should always be performed in patients who demonstrate abnormal uterine bleeding or other signs of endometrial abnormalities before starting FSH and Ovidrel ® PreFilled Syringe therapy. Evaluation of the partner's fertility potential should be included in the initial evaluation.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
2 products under this application
- OVIDREL · CHORIOGONADOTROPIN ALFA 0.25MG/VIAL · INJECTABLE, INJECTION · Discontinued
- OVIDREL · CHORIOGONADOTROPIN ALFA EQ 0.25MG /0.5ML · INJECTABLE, SUBCUTANEOUS · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Choriogonadotropin Alfa" as an intervention, any sponsor and status, largest first.
- A Study to Investigate the Efficacy and Safety of a Single Injection of Corifollitropin Alfa (Organon 36286) for Ovarian Stimulation Using Daily Recombinant Follicle Stimulating Hormone (FSH) as Reference (P05787)Pivotal-lookingCompleted
Organon and CoIndustry
NCT00696800 · 1,509 participants · Start Jun 27, 2006 · Primary completion Nov 19, 2007
Drug: Corifollitropin alfa; RecFSH / Follitropin beta (Days 1 to 7) and 6 more · For: In Vitro Fertilization
- Phase III Study Comparing Efficacy and Safety of AFOLIA vs Gonal-f® RFF in Women (35 to 42) Undergoing IVFPivotal-lookingCompleted
Fertility Biotech AGIndustry
NCT01687712 · 1,100 participants · Start Nov 25, 2013 · Primary completion Sep 10, 2015
Drug: AFOLIA; Gonal-f® RFF · For: Infertility
Sites: Tempe, Arizona; Encino, California; Newark, Delaware · 22 sites in all
- Phase 3 Study to Evaluate the Efficacy and Safety of Pergoveris® in Assisted Reproductive Technology (ESPART)Pivotal-lookingCompleted
Merck KGaA, Darmstadt, GermanyIndustry
NCT02047227 · 939 participants · Start Jan 31, 2014 · Primary completion Aug 31, 2015
Drug: Pergoveris®; GONAL-f® and 1 more · For: Infertility
Sites: Darmstadt, Germany
Lund UniversityAcademic, hospital or other
NCT03737253 · 810 participants · Start Sep 2016 · Primary completion Dec 31, 2021
Drug: Follitropin alpha; Menotropin · For: Female Infertility
Sites: Poznan, Poland; Malmö, Sweden
- A Trial to Investigate the Efficacy and Safety of FE 999302 as add-on Treatment to Follitropin Delta (REKOVELLE) in Women Undergoing Controlled Ovarian Stimulation.Pivotal-lookingCompleted
Ferring PharmaceuticalsIndustry
NCT03564509 · 620 participants · Start May 14, 2018 · Primary completion Oct 21, 2019
Drug: FE 999302 (1 μg) and follitropin delta; FE 999302 (2 μg) and follitropin delta and 3 more · For: Controlled Ovarian Stimulation
Sites: Ghent, Belgium; Jette, Belgium; Karlovy Vary, Czechia · 20 sites in all
- Extra Luteinizing Hormone Improve Embryo Quality in IVF Patients With Low LH During Long GnRH-Agonist TreatmentPivotal-lookingRecruiting
Nanjing UniversityAcademic, hospital or other
NCT07128394 · 590 participants (planned) · Start Feb 1, 2024 · Primary completion Sep 30, 2026
Drug: Recombinant Luteinizing Hormone (rLH); Recombinant Follicle-Stimulating Hormone (rFSH) and 1 more · For: Infertility, Female; Luteinizing Hormone (LH)
Sites: Nanjing, China
- Nordic Luveris StudyPivotal-lookingCompleted
Copenhagen University Hospital, RigshospitaletAcademic, hospital or other
NCT00553293 · 526 participants · Start Aug 2003
Drug: recombinant luteinizing hormone (Luveris); recombinant follicle stimulating hormone (Gonal-f) · For: Infertility; In Vitro Fertilization
Sites: Copenhagen, Denmark
- Investigation of a Long-Acting Follicle Stimulating Hormone in Infertile Women Undergoing Assisted Reproductive Technology (ART)Pivotal-lookingCompleted
Merck KGaA, Darmstadt, GermanyIndustry
NCT00505752 · 520 participants · Start Jan 2007 · Primary completion Sep 2008
Drug: AS900672-Enriched 50 microgram (mcg); AS900672-Enriched 100 mcg and 3 more · For: Infertility
Sites: Rockland, Massachusetts
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- ovarian hyperstimulation syndrome448
- ascites83
- abdominal distension74
- abdominal pain70
- nausea62
- off label use62
- dyspnoea51
- pleural effusion48
- abortion spontaneous46
- maternal exposure during pregnancy40
- headache38
- vomiting37
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 5 |
| 2005 | 4 |
| 2006 | 6 |
| 2007 | 16 |
| 2008 | 8 |
| 2009 | 11 |
| 2010 | 10 |
| 2011 | 18 |
| 2012 | 27 |
| 2013 | 30 |
| 2014 | 26 |
| 2015 | 11 |
| 2016 | 24 |
| 2017 | 15 |
| 2018 | 32 |
| 2019 | 64 |
| 2020 | 43 |
| 2021 | 84 |
| 2022 | 163 |
| 2023 | 150 |
| 2024 | 175 |
| 2025 | 114 |
| 2026 | 127 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Pharmacokinetics and Safety Profile of DA-3803, a Proposed Biosimilar of Recombinant Human Chorionic Gonadotropin, in Healthy Subjects.
Cha YJ, Kim KA, Oh TY, et al. · BioDrugs 2015 · Randomized Controlled Trial
- Gateways to clinical trials.
Bayés M, Rabasseda X, Prous JR · Methods Find Exp Clin Pharmacol 2004 · Clinical Trial
- Human choriogonadotropin and epoetin alfa in acute ischemic stroke patients (REGENESIS-LED trial).
Cramer SC, Hill MD · Int J Stroke 2014 · Multicenter Study, Randomized Controlled Trial
- Efficacy of luteinizing hormone activity in patients undergoing in vitro fertilization and treated only with low-dose recombinant choriogonadotropin alfa (Ovidrel) in the late follicular phase.
Kenigsberg D, Madankumar R, Moodie G, et al. · Fertil Steril 2006 · Clinical Trial, Research Support, Non-U.S. Gov't
- Recombinant human chorionic gonadotropin (rhCG) in assisted reproductive technology: results of a clinical trial comparing two doses of rhCG (Ovidrel) to urinary hCG (Profasi) for induction of final follicular maturation in in vitro fertilization-embryo transfer.
Chang P, Kenley S, Burns T, et al. · Fertil Steril 2001 · Clinical Trial, Comparative Study
- Comparative Pharmacokinetics, Bioequivalence and Safety Study of Two Recombinant Human Chorionic Gonadotropin Injections in Healthy Chinese Subjects.
Wang J, Yang T, Mei H, et al. · Drug Des Devel Ther 2020 · Clinical Trial, Phase I, Comparative Study
Sponsor: Emd Serono
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.